

# Roberto Sabbatini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1464769/publications.pdf>

Version: 2024-02-01

64  
papers

3,835  
citations

236925

25  
h-index

128289

60  
g-index

65  
all docs

65  
docs citations

65  
times ranked

6250  
citing authors

#	ARTICLE	IF	CITATIONS
1	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	2.0	7
2	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
3	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	1.1	8
4	TERT promoter methylation and protein expression as predictive biomarkers for recurrence risk in patients with serous borderline ovarian tumours. <i>Pathology</i> , 2021, 53, 187-192.	0.6	2
5	Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report. <i>Tumori</i> , 2021, 107, 030089162199073.	1.1	2
6	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. <i>Cancer Treatment Reviews</i> , 2021, 94, 102157.	7.7	16
7	Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 1669.	12.8	48
8	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	10.7	215
9	Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1183-1192.	2.4	0
10	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	2.8	8
11	Long survival of a young patient with Xp11.2 translocation metastatic clear cell renal carcinoma: case report and review of the literature. <i>Tumori</i> , 2021, 107, 030089162110492.	1.1	4
12	Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. <i>Immunotherapy</i> , 2021, 13, 1501-1519.	2.0	5
13	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). <i>Frontiers in Oncology</i> , 2021, 11, 787835.	2.8	9
14	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
15	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 140, 140-146.	2.8	18
16	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	1.9	15
17	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020, 12, 151-159.	2.0	16
18	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	4.8	38

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
20	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? <i>The GIANUS Review. Critical Reviews in Oncology/Hematology</i> , 2019, 139, 149-157.	4.4	10
21	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	4.4	15
22	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	1.9	30
23	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
24	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	3.7	131
25	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
26	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
27	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 529.e1-529.e7.	1.6	5
28	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
29	Practical issues for the management of hyponatremia in oncology. <i>Endocrine</i> , 2018, 61, 158-164.	2.3	19
30	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018, 24, 447-456.	1.9	20
31	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. <i>The INVIDIA study. Immunotherapy</i> , 2018, 10, 1229-1239.	2.0	38
32	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	2.4	3
33	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
34	Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. <i>PLoS ONE</i> , 2018, 13, e0199642.	2.5	23
35	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
36	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 705-709.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	1.6	10
38	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017, 92, 269-275.	1.9	5
39	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
40	Toward the future of the functional imaging of advanced prostate cancer. <i>European Urology Focus</i> , 2017, 3, 240-242.	3.1	4
41	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
42	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	2.4	10
43	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
44	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
45	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
46	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
47	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12
48	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- $\gamma$ (IFN- $\gamma$ ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	2.4	61
49	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	1.6	355
50	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
51	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 697-709.	2.4	12
52	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013, 9, 831-843.	2.4	7
53	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66
54	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1089-1096.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1571-1577.	2.4	35
56	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
57	Bevacizumab plus Interferon- $\alpha$ versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. <i>Clinical Drug Investigation</i> , 2011, 31, 507-517.	2.2	12
58	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011, 108, E250-E257.	2.5	79
59	Expression pattern of receptor activator of NF $\kappa$ B (RANK) in a series of primary solid tumors and related bone metastases. <i>Journal of Cellular Physiology</i> , 2011, 226, 780-784.	4.1	118
60	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- $\alpha$ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	4.2	22
61	Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting. <i>Current Cancer Drug Targets</i> , 2010, 10, 46-54.	1.6	24
62	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi ( GISL ) Prognostic Criteria for Watch and Wait Policy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1933-1938.	1.3	8
63	Detection of Circulating Tumor Cells by Reverse Transcriptase Polymerase Chain Reaction of Maspin in Patients With Breast Cancer Undergoing Conventional-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1914-1920.	1.6	48
64	Prevention of Cisplatin-Induced Vomiting in Patients with Cancer. A Pilot Study with a Multiagent Protocol. <i>Tumori</i> , 1990, 76, 278-281.	1.1	2